The pancreas is an organ of the abdominal cavity and is involved in the digestion of food. When cancer cells get out of control, they can degenerate into cancerous tumors. This disease is difficult to detect and diagnose in the early stages because it usually occurs without noticeable signs or symptoms. Furthermore, when symptoms did occur, they are similar to symptoms of other pathologies. Approximately one in 60 adult affects pancreatic cancer, and of less than 5% of patients are living longer than 5 years. Hence the relevance of the development of new methods to prevent the disease is high.
To research the research team chose subjects from 30 general hospitals in the state of Connecticut. Were registered 362 patients with pancreatic cancer and 690 people in the control group. Scientists wondered when patients began taking aspirin, how long they drank it, the dosage, and when they finished the medication. The team took into account factors such as body mass index, presence of diabetes and smoking. 96% of participants were taking low-dose aspirin, which were determined in the range of 75-325 mg per day. That is the amount of drug typically prescribed by physicians for the prevention of cardiovascular diseases.
Researchers have found that the earlier a person starts to take low-dose aspirin, the significantly reduces the risk of developing pancreatic cancer. In particular, those who started taking aspirin for 3 years prior to the study, the risk was 48% lower. And those who used it for over 20 years to participate in the experiment, had a risk of 60% less. In addition, those patients who stopped taking the drug after 2years after the study began, three times increased risk of developing pancreatic cancer. Dr. Risch said that now there is strong evidence that people who drink aspirin to reduce the risk of cardiovascular disease, receive an additional benefit from this, because this drug helps prevent cancer of the pancreas.